CLRB - Cellectar Biosciences

-

$undefined

N/A

(N/A)

Cellectar Biosciences NasdaqCM:CLRB Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Location: 100 Campus Drive, Florham Park, NJ, 07932, United States | Website: https://www.cellectar.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-745K

Cash

13.91M

Avg Qtr Burn

-10.9M

Short % of Float

5.28%

Insider Ownership

1.71%

Institutional Own.

12.42%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iopofosine (CLR 131) Details
Cancer, B-cell lymphoma, Lymphoma

Phase 2

Update

Iopofosine (CLR 131) Details
Multiple myeloma, Cancer, High Refractory Multiple Myeloma

Phase 2

Update

Iopofosine (CLR 131) Details
Waldenstrom macroglobulinemia

Phase 2

Update

CLR 121125 Details
Triple-negative breast cancer

Phase 1/2

Initiation

Iopofosine (CLR 131) Details
Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma

Phase 1b

Data readout

Iopofosine (CLR 131) + EBRT Details
Head and neck cancer, Head and neck squamous cell carcinoma

Phase 1

Update